News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Moomoo Earnings
Femasys reported a second-quarter loss per share of $1.33. This financial update indicates the company's performance for the recent quarter.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Femasys (FEMY) reported a Q2 2026 revenue of $331,827, an 18.9% decrease year-over-year, and a net loss of $4.47 million. Despite the revenue decline, the company completed a $30 million private placement and launched FemaSeed Complete, while insiders made multiple stock purchases, indicating confidence …
Femasys Inc. (NASDAQ: FEMY) reported a narrowed net loss for the first half of 2026, totaling $3,622,995, a significant improvement from $10,482,761 in the prior-year period. The company also announced the completion of a $30 million private placement, which is expected to strengthen its …
Maxim Group has reiterated its Buy rating on Femasys (FEMY.US) but has adjusted its price target downwards to $10. This indicates continued confidence in the company's prospects despite a revised valuation.
Investment entities affiliated with Rosalind Advisors Inc. have reported a potential beneficial ownership of up to 9.99% in Femasys Inc. (FEMY) common shares. This stake includes 723,377 common shares and an additional 3,964,123 shares issuable upon warrant exercise, though blocker provisions cap the effective …
Femasys Inc. announced the issuance of new patents in the U.S. and internationally for the blended polymer component of its FemBloc non-surgical permanent birth control technology. These patents expand and strengthen the global intellectual property protection for FemBloc, complementing existing patents for its delivery …
Femasys CFO Dov Elefant recently purchased $50,000 worth of company common stock at $3.20 per share, a price significantly above its current trading value near a 52-week low. Elefant also acquired two types of common stock purchase warrants, one standard and one milestone-based, with …
Femasys (NASDAQ: FEMY) announced the issuance of new patents in the United States and several international markets for the blended polymer component of its non-surgical permanent birth control technology, FemBloc. These patents enhance FemBloc's intellectual property protection, complementing existing patents for its delivery system. …
Femasys CTO Jeremy Sipos purchased $10,000 worth of the company's common stock and warrants, acquiring 3,125 shares at $3.20 each, and two types of warrants for an additional 3,125 shares each. This insider buying comes as the stock trades near its 52-week low, with …
Femasys COO John Canning recently purchased 4,375 shares of FEMY common stock for $14,000, at a price of $3.20 per share, when the stock was trading near its 52-week low. He also acquired two types of common stock purchase warrants, both with an exercise …
John Canning, COO of Femasys Inc. (NASDAQ: FEMY), recently purchased 4,375 shares of company stock for $14,000 at $3.20 per share, along with two types of warrants. This transaction occurred while FEMY stock trades near its 52-week low, and InvestingPro analysis suggests the stock …
Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs at Femasys Inc. (NASDAQ:FEMY), recently purchased $10,000 worth of common stock and acquired two warrants. The stock purchase was at $3.20 per share, above the current trading price, with one warrant exercisable soon and another tied to significant …
Femasys (FEMY) has completed a $30 million private placement of common stock and warrants to strengthen liquidity and fund growth. The agreement also includes registration rights for investors and grants Nantahala Capital Management board representation based on ownership thresholds. Concurrently, previous board nomination and …
Femasys CEO Kathy Lee-Sepsick purchased 15,625 shares of FEMY stock for $50,000, along with two types of warrants, indicating confidence in the company, especially as the stock trades near its 52-week low. This insider purchase follows recent positive developments for Femasys, including regaining Nasdaq …
Femasys Inc. has secured a $30 million private placement through the sale of common stock and a significant package of pre-funded and accompanying warrants to accredited investors. The deal includes board designation rights for lead investor Nantahala Capital Management and involves participation from five …
(RTTNews) - Femasys Inc. (FEMY) announced that it has entered into a securities purchase agreement for a $30 million private placement of shares and warrants led by Nantahala Capital. Under the terms of the agreement, Femasys is selling to the investors an aggregate of …
Femasys Inc. announced a $30 million private placement led by Nantahala Capital, involving the sale of common stock and pre-funded warrants along with accompanying warrants. The financing could yield up to an additional $60 million if all warrants are exercised for cash, with some …
This article provides the "Price to earnings forward" metric for Femasys Inc. (NASDAQ: FEMY). It is presented within the context of TradingView's financial data offerings, indicating the company's stock market information. The content itself is very minimal, focusing solely on this single financial data …
This article provides financial data for Femasys Inc. (NASDAQ: FEMY), specifically its enterprise value to EBIT forward. It is presented through TradingView, a platform offering market data and financial tools.
Femasys Inc. (FEMY) shares dropped 11.07% on Friday following the announcement of a $30 million private placement with accredited investors, including Nantahala Capital, Rosalind Advisors, and company management. The agreement involves the sale of 9.37 million shares of common stock and pre-funded warrants, plus …
Femasys has priced a $30 million private placement of common stock, pre-funded warrants, and accompanying warrants with accredited investors at $3.20 per share. The deal includes 9,374,999 common shares and pre-funded warrants, each paired with two 3-year warrants covering 18,749,998 shares, with an exercise …
Femasys (NASDAQ: FEMY) has entered into a $30 million private placement agreement with accredited investors, led by Nantahala Capital. The deal involves selling common shares and pre-funded warrants, bundled with accompanying warrants, which if fully exercised for cash, could provide Femasys with an additional …
Femasys Inc. announced a $30 million private placement financing agreement with accredited investors, led by Nantahala Capital, with participation from other healthcare funds and Femasys management. The deal involves selling common stock and pre-funded warrants with accompanying warrants, potentially raising an additional $60 million …
Femasys Inc. announced a $30 million private placement led by Nantahala Capital, involving the sale of common stock and pre-funded warrants along with accompanying warrants. The financing could yield up to an additional $60 million if all warrants are exercised for cash, with some …
Femasys Inc. (FEMY) is scheduled to announce its Q2'26 earnings on August 12, 2026. The company is projected to report an estimated revenue of 730.67 thousand USD and an EPS of (1.27) USD for the quarter. The article provides a detailed table of past …
Femasys Inc is projected to report an earnings loss of $1.30 per share. This information is provided as an earnings preview from Refinitiv, indicating upcoming financial results for the company.
This article provides a brief snapshot of Femasys Inc. (NASDAQ: FEMY) on TradingView, specifically focusing on its forward price-to-book ratio. The content indicates that the market was closed at the time of viewing, with no trades observed. It also lists various data sources and …
This article analyzes the financial health of Femasys Inc (FEMY), noting its current financial score is 5.08, ranking 197 out of 199 in its industry. The company shows stable financial status and low operating efficiency, with recent quarterly revenue increasing by 24.50% and net …
This article provides a brief financial overview of Femasys Inc. (NASDAQ: FEMY), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or snippet from a larger financial data platform like TradingView, indicating where more detailed financial information can be found …
This article assesses the risk profile of Femasys Inc (FEMY), highlighting its current risk assessment score of 1.28, which ranks it 184th out of 199 companies in the Healthcare Equipment & Supplies industry. Key metrics include a beta value of -2.13, indicating defensive stock …
Search by ticker symbol or company name and select a result to open its chart.